Endra Life Sciences (NDRA) Presents At H.C. Wainwright 21st Annual Global Investment Conference - Slideshow

ENDRA Life Sciences Overview - ENDRA Life Sciences is pioneering breakthrough ultrasound applications[2] - The company focuses on visualizing human tissue like CT or MRI but at a 50X lower cost at the point of patient care[9] - ENDRA's platform technology initially focuses on NAFLD-NASH, representing a $13B greenfield opportunity to expand clinical applications for 1M+ installed ultrasound systems[9] - The company has a strong technology position with 58 IP assets[9] TAEUS™ Technology and Applications - ENDRA's Thermo Acoustic Enhanced UltraSound (TAEUS™) differentiates tissues in concert with ultrasound[18] - The initial application is focused on diagnosing NAFLD by tissue composition[21] - TAEUS™ platform has multiple potential revenue streams including accessories, software, licensing, service, and disposables[21] Market and Commercialization - The addressable market for ENDRA's TAEUS platform is approximately 338,000 cart-based non-prenatal ultrasound systems, representing a $13B+ market opportunity[25, 26] - Over 1.4 billion people globally are affected by NAFLD-NASH, creating a significant clinical need for a non-invasive, cost-effective diagnostic tool[9, 27] - ENDRA has a partnership with GE Healthcare focused on early assessment of non-alcoholic fatty liver disease[31] Financials and Key Statistics - As of August 30, 2019, ENDRA's common stock price was $1.70, with a market capitalization of $12.6M[45] - Management and director ownership was 12.9%[45]